NEWS: 公告在东京证券交易所JASDAQ标准市场新上市

表纸
市场调查报告书

胰脏癌症:市场机会分析、预测 (~2029年)

Pancreatic Cancer - Opportunity Analysis and Forecasts to 2029

出版商 GlobalData 商品编码 979396
出版日期 内容资讯 英文 146 Pages
订单完成后即时交付
价格
胰脏癌症:市场机会分析、预测 (~2029年) Pancreatic Cancer - Opportunity Analysis and Forecasts to 2029
出版日期: 2020年12月31日内容资讯: 英文 146 Pages
简介

胰脏癌,现在在世界是第7大的癌症相关的死因,2018年造成432,242人的死亡。外分泌性胰脏癌症分类的胰脏腺癌症 (PDAC) 是最常见类型的胰脏癌症,占全部的胰脏癌症诊断的80%。

本报告提供全球主要8个国家胰脏癌症的市场调查,疾病概要,病因、病理生理学,诊断病例数的变化、预测,目前治疗选择,未满足需求,开发平台趋势,已上市产品趋势,市场规模的变化、预测,未来展望等汇整资料。

第1章 目录

第2章 摘要整理

第3章 简介

第4章 疾病概要

  • 病因、病理生理学
  • 分类、癌症分期系统

第5章 流行病学

  • 病的背景
  • 危险因素、合并症
  • 全球趋势、历史的趋势
  • 预测调查手法
  • 胰脏癌症的流行病学预测
    • 胰脏癌症的诊断病例数
    • PDAC的诊断病例数
    • PDAC的诊断病例数:男女
    • PDAC的诊断病例数:各年龄
    • PDAC的诊断病例数:各阶段
    • 遗传性PDAC的诊断病例数:各生殖细胞变异
    • PDAC的诊断病例数:各KRAS、NTRK遗传基因变异
    • PDAC的诊断病例数:各PD-L1表现
    • PDAC的5年诊断患者数
  • 讨论

第6章 目前治疗选择

第7章 未满足需求、市场机会的评估

第8章 R&D策略

  • 概要
  • 临床试验设计

第9章 开发平台评估

  • 概要
  • 创新的初期方法
    • 嵌合抗原受体 (CAR) T细胞疗法
    • 基因治疗
    • 癌症疫苗
  • 开发中的其他药剂

第10章 开发平台评估分析

  • 主要的开发平台药物临床基准
  • 主要的开发平台药物的商业性基准
  • 竞争评估
  • Top line 10年预测
    • 美国
    • 欧盟5国
    • 日本
    • 中国都市区
    • 总论

第11章 附录

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: GDHC120POA

Pancreatic Cancer - Opportunity Analysis and Forecasts to 2029

Pancreatic cancer is currently the fourth leading cause of cancer-related deaths in the United States, following lung cancer and breast cancer and seventh leading cause of cancer related deaths worldwide with 432,242 related deaths being reported in 2018. Pancreatic adenocarcinoma (PDAC), classified as an exocrine pancreatic cancer, is considered to be the most common type of pancreatic cancer, accounting for 80% of all pancreatic cancer diagnoses.

The treatment paradigm for pancreatic cancer is predominantly composed of chemotherapies, most notably FOLFIRINOX and gemcitabine-based therapies, which are considered to be gold standard for pancreatic cancer. In patients exhibiting genetic mutations, targeted therapies such as Vitrakvi (larotrectinib), Rozlytrek (entrectinib), Poly (ADP-ribose) polymerase (PARP) inhibitor Lynparza (olaparib), and Keytruda (pembrolizumab) are currently included in treatment guidelines across the 8MM. CP-613 (devimistat) and TAK-931 (simurosertib) are the lead pipeline candidates in 1L setting. This indication will also se introduction of 2 strong pipeline agents in 3L setting.

Key Highlights

  • The main drivers of growth include the anticipated approval and launch of 10 pipeline therapies, in addition to label expansions of currently marketed therapies across the 8MM during the forecast period.
  • The main barriers to growth in the 8MM include the patent expiry of major brands and the high price of premium priced therapeutics entering the market.
  • Among the late-stage pipeline products and marketed agents, TAK-931 (simurosertib) and CP-613 (devimistat) are expected to generate the greatest revenues over the forecast period.
  • The most important unmet needs in the pancreatic cancer market include: effective treatment options that prolong survival in advanced or metastatic settings, early diagnosis and tumor targeting drugs with novel mechanisms of actions.

KEY QUESTIONS ANSWERED

  • Ten late-stage pipeline agents are going to enter the pancreatic cancer market from 2019 onwards. Will the impact will these agents have on the market? Which of these drugs will have the highest peak sales, and why?
  • What are the current unmet needs in pancreatic cancer, which pipeline agents are positioned to counter these unmet needs? What are the opportunities for R&D?
  • What is the market outlook in the 8MM from 2019-2029? Considering major patent expiries, launch of new premium priced agents and expected label expansions.
  • What are the main corporate trends? Who are the current and future players?

Scope

  • Overview of pancreatic cancer including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Topline pancreatic cancer market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
  • Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting pancreatic cancer therapeutics sales in the 8MM.
  • Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs (Phase III).
  • Analysis of the current and future market competition in the global pancreatic cancer therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
  • Develop business strategies by understanding the trends shaping and driving the global pancreatic cancer therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global pancreatic cancer market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global pancreatic cancer therapeutics market from 2019-2029.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Pancreatic Cancer: Executive Summary

  • 2.1 Global Pancreatic Cancer Market Expected to Grow at 11.5% CAGR to $5.4B During 2019-2029
  • 2.2 Assessing Viability of Novel Tumor Targeting Therapies - A Key Focus of Current Clinical Development
  • 2.3 Lack of Effective Treatment Options - Highest Unmet Need in PDAC
  • 2.4 High Opportunity for Pipeline Agents Demonstrating Increased Overall Survival
  • 2.5 Targeted Therapies Provide a Brighter Outlook for PDAC
  • 2.6 What Do Physicians Think?

3 Introduction

  • 3.1 Catalyst
  • 3.2 Related Reports
  • 3.3 Upcoming Related Reports

4 Disease Overview

  • 4.1 Etiology and Pathophysiology
    • 4.1.1 Etiology
    • 4.1.2 Pathophysiology
  • 4.2 Classification or Staging Systems

5 Epidemiology

  • 5.1 Disease Background
  • 5.2 Risk Factors and Comorbidities
  • 5.3 Global and Historical Trends
  • 5.4 Forecast Methodology
    • 5.4.1 Sources Used
    • 5.4.2 Forecast Assumptions and Methods
    • 5.4.3 Diagnosed Incident Cases of Pancreatic Cancer and PDAC
    • 5.4.4 Diagnosed Incident Cases of PDAC by Stages
    • 5.4.5 Diagnosed Incident Cases of PDAC by Familial PDAC by Germline Mutation
    • 5.4.6 Diagnosed Incident Cases of PDAC by KRAS and NTRK Gene Fusion Mutation
    • 5.4.7 Diagnosed Incident Cases of PDAC by PD-L1 Expression
    • 5.4.8 Five-Year Diagnosed Prevalent Cases of PDAC
  • 5.5 Epidemiological Forecast for Pancreatic Cancer, 2019-2029
    • 5.5.1 Diagnosed Incident Cases of Pancreatic Cancer
    • 5.5.2 Diagnosed Incident Cases of PDAC
    • 5.5.3 Sex-Specific Diagnosed Incident Cases of PDAC
    • 5.5.4 Age-Specific Diagnosed Incident Cases of PDAC
    • 5.5.5 Diagnosed Incident Cases of PDAC by Stage at Diagnosis
    • 5.5.6 Diagnosed Incident Cases of Familial PDAC by Germline Mutations
    • 5.5.7 Diagnosed Incident Cases of PDAC by KRAS and NTRK Gene Mutations
    • 5.5.8 Diagnosed Incident Cases of PDAC by PD-L1 Expression
    • 5.5.9 Five-Year Diagnosed Prevalent Cases of PDAC
  • 5.6 Discussion
    • 5.6.1 Epidemiological Forecast Insight
    • 5.6.2 COVID-19 Impact
    • 5.6.3 Limitations of Analysis
    • 5.6.4 Strengths of Analysis

6 Current Treatment Options

  • 6.1 Overview

7 Unmet Needs and Opportunity Assessment

  • 7.1 Overview
  • 7.2 Early Detection
  • 7.3 Expansion of Eligible Patient Population and Need for the Discovery of New Biomarkers
  • 7.4 Increased Availability of Treatment Options
  • 7.5 Treatment Options in the Third-Line Setting
  • 7.6 Prolonged Life Expectancy/Survival

8 R&D Strategies

  • 8.1 Overview
    • 8.1.1 Drugs Targeting Tumor Immune Evasion Mechanisms
    • 8.1.2 Expansion into Neoadjuvant and Adjuvant Settings
    • 8.1.3 Explore Viability of Novel Targets and Mechanism of Action
    • 8.1.4 Reformulation of Marketed Drugs
    • 8.1.5 Therapy Sequencing
  • 8.2 Clinical Trials Design
    • 8.2.1 Key Clinical Trials
    • 8.2.2 Primary and Secondary Endpoints
    • 8.2.3 Trial Design Characteristics

9 Pipeline Assessment

  • 9.1 Overview
  • 9.2 Innovative Early-Stage Approaches
    • 9.2.1 Chimeric Antigen Receptor (CAR) T-Cell Therapy
    • 9.2.2 Gene therapy
    • 9.2.3 Cancer vaccine
  • 9.3 Other Drugs in Development

10 Pipeline Valuation Analysis

  • 10.1 Clinical Benchmark of Key Pipeline Drugs
  • 10.2 Commercial Benchmark of Key Pipeline Drugs
  • 10.3 Competitive Assessment
  • 10.4 Top-Line 10-Year Forecast
    • 10.4.1 US
    • 10.4.2 5EU
    • 10.4.3 Japan
    • 10.4.4 Urban China
    • 10.4.5 Conclusion

11 Appendix

List of Tables

List of Tables

  • Table 1: Pancreatic Cancer: Key Metrics in the 8MM
  • Table 2: Selected Genetic Syndromes with Associated Pancreatic Cancer Risk
  • Table 3: AJCC TNM classification System for Pancreatic Cancer
  • Table 4: AJCC TNM Staging System for Pancreatic Cancer
  • Table 5: Risk Factors and Comorbidities for PDAC
  • Table 6: Current Leading Treatments for Pancreatic Cancer, 2019
  • Table 7: Key Pipeline Agents in Development for Pancreatic cancer, 2019-2029
  • Table 8: Key Phase II/III Clinical Trials in Pancreatic Cancer, 2019-2029
  • Table 9: Comparison of Therapeutic Classes in Development for Pancreatic Cancer, 2019-2029
  • Table 10: Leading Pharmaceutical Companies Innovating in CAR-T Therapy in 2019
  • Table 11: Drugs in Development for Pancreatic Cancer, 2019-2029
  • Table 12: Clinical Benchmarking of Key Marketed & Pipeline Products - First Line
  • Table 13: Clinical Benchmarking of Key Marketed & Pipeline Products - Second Line
  • Table 14: Commercial Benchmarking of Key Marketed & Pipeline Products - First Line
  • Table 15: Commercial Benchmarking of Key Marketed & Pipeline Products - Second Line
  • Table 16: Key Events Impacting Sales for Pancreatic Cancer in the US, 2019-2029
  • Table 17: Pancreatic Cancer Market - Global Drivers and Barriers, 2019-2029
  • Table 18: Key Historical and Projected Launch Dates for Pancreatic Cancer
  • Table 19: Key Historical and Projected Patent Expiry Dates for Pancreatic Cancer
  • Table 20: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

List of Figures

  • Figure 1: Global Sales Forecast by Country for Pancreatic Cancer in 2019 and 2029
  • Figure 2: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the Standard of Care, FOLFIRINOX - First Line
  • Figure 3: Competitive A